Cargando…

The Within-Group Discrimination Ability of the Cancer of the Prostate Risk Assessment Score for Men with Intermediate-Risk Prostate Cancer

BACKGROUND: Significant clinical heterogeneity within contemporary risk group is well known, particularly for those with intermediate-risk prostate cancer (IRPCa). Our study aimed to analyze the ability of the Cancer of the Prostate Risk Assessment (CAPRA) score to discern between favorable and non-...

Descripción completa

Detalles Bibliográficos
Autores principales: Kang, Ho Won, Jung, Hae Do, Lee, Joo Yong, Kwon, Jong Kyou, Jeh, Seong Uk, Cho, Kang Su, Ham, Won Sik, Choi, Young Deuk
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Academy of Medical Sciences 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5773849/
https://www.ncbi.nlm.nih.gov/pubmed/29349945
http://dx.doi.org/10.3346/jkms.2018.33.e36
_version_ 1783293648676323328
author Kang, Ho Won
Jung, Hae Do
Lee, Joo Yong
Kwon, Jong Kyou
Jeh, Seong Uk
Cho, Kang Su
Ham, Won Sik
Choi, Young Deuk
author_facet Kang, Ho Won
Jung, Hae Do
Lee, Joo Yong
Kwon, Jong Kyou
Jeh, Seong Uk
Cho, Kang Su
Ham, Won Sik
Choi, Young Deuk
author_sort Kang, Ho Won
collection PubMed
description BACKGROUND: Significant clinical heterogeneity within contemporary risk group is well known, particularly for those with intermediate-risk prostate cancer (IRPCa). Our study aimed to analyze the ability of the Cancer of the Prostate Risk Assessment (CAPRA) score to discern between favorable and non-favorable risk in patients with IRPCa. METHODS: We retrospectively reviewed the data of 203 IRPCa patients who underwent extraperitoneal robot-assisted radical prostatectomy (RARP) performed by a single surgeon. Pathologic favorable IRPCa was defined as a Gleason score ≤ 6 and organ-confined stage at surgical pathology. The CAPRA score was compared with two established criteria for the within-group discrimination ability. RESULTS: Overall, 38 patients (18.7% of the IRPCa cohort) had favorable pathologic features after RARP. The CAPRA score significantly correlated with established criteria I and II and was inversely associated with favorable pathology (all P < 0.001). The area under the receiver operating characteristic curve for the discriminative ability between favorable and non-favorable pathology was 0.679 for the CAPRA score and 0.610 and 0.661 for established criteria I and II, respectively. During a median 37.8 (interquartile range, 24.6–60.2) months of follow-up, 66 patients (32.5%) experienced biochemical recurrence (BCR). Cox regression analysis revealed that the CAPRA score, as a continuous sum score model or 3-group risk model, was an independent predictor of BCR after RARP. CONCLUSION: The within-group discrimination ability of preoperative CAPRA score might help in patient counseling and selecting optimal treatments for those with IRPCa.
format Online
Article
Text
id pubmed-5773849
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher The Korean Academy of Medical Sciences
record_format MEDLINE/PubMed
spelling pubmed-57738492018-01-29 The Within-Group Discrimination Ability of the Cancer of the Prostate Risk Assessment Score for Men with Intermediate-Risk Prostate Cancer Kang, Ho Won Jung, Hae Do Lee, Joo Yong Kwon, Jong Kyou Jeh, Seong Uk Cho, Kang Su Ham, Won Sik Choi, Young Deuk J Korean Med Sci Original Article BACKGROUND: Significant clinical heterogeneity within contemporary risk group is well known, particularly for those with intermediate-risk prostate cancer (IRPCa). Our study aimed to analyze the ability of the Cancer of the Prostate Risk Assessment (CAPRA) score to discern between favorable and non-favorable risk in patients with IRPCa. METHODS: We retrospectively reviewed the data of 203 IRPCa patients who underwent extraperitoneal robot-assisted radical prostatectomy (RARP) performed by a single surgeon. Pathologic favorable IRPCa was defined as a Gleason score ≤ 6 and organ-confined stage at surgical pathology. The CAPRA score was compared with two established criteria for the within-group discrimination ability. RESULTS: Overall, 38 patients (18.7% of the IRPCa cohort) had favorable pathologic features after RARP. The CAPRA score significantly correlated with established criteria I and II and was inversely associated with favorable pathology (all P < 0.001). The area under the receiver operating characteristic curve for the discriminative ability between favorable and non-favorable pathology was 0.679 for the CAPRA score and 0.610 and 0.661 for established criteria I and II, respectively. During a median 37.8 (interquartile range, 24.6–60.2) months of follow-up, 66 patients (32.5%) experienced biochemical recurrence (BCR). Cox regression analysis revealed that the CAPRA score, as a continuous sum score model or 3-group risk model, was an independent predictor of BCR after RARP. CONCLUSION: The within-group discrimination ability of preoperative CAPRA score might help in patient counseling and selecting optimal treatments for those with IRPCa. The Korean Academy of Medical Sciences 2017-12-08 /pmc/articles/PMC5773849/ /pubmed/29349945 http://dx.doi.org/10.3346/jkms.2018.33.e36 Text en © 2018 The Korean Academy of Medical Sciences. https://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Kang, Ho Won
Jung, Hae Do
Lee, Joo Yong
Kwon, Jong Kyou
Jeh, Seong Uk
Cho, Kang Su
Ham, Won Sik
Choi, Young Deuk
The Within-Group Discrimination Ability of the Cancer of the Prostate Risk Assessment Score for Men with Intermediate-Risk Prostate Cancer
title The Within-Group Discrimination Ability of the Cancer of the Prostate Risk Assessment Score for Men with Intermediate-Risk Prostate Cancer
title_full The Within-Group Discrimination Ability of the Cancer of the Prostate Risk Assessment Score for Men with Intermediate-Risk Prostate Cancer
title_fullStr The Within-Group Discrimination Ability of the Cancer of the Prostate Risk Assessment Score for Men with Intermediate-Risk Prostate Cancer
title_full_unstemmed The Within-Group Discrimination Ability of the Cancer of the Prostate Risk Assessment Score for Men with Intermediate-Risk Prostate Cancer
title_short The Within-Group Discrimination Ability of the Cancer of the Prostate Risk Assessment Score for Men with Intermediate-Risk Prostate Cancer
title_sort within-group discrimination ability of the cancer of the prostate risk assessment score for men with intermediate-risk prostate cancer
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5773849/
https://www.ncbi.nlm.nih.gov/pubmed/29349945
http://dx.doi.org/10.3346/jkms.2018.33.e36
work_keys_str_mv AT kanghowon thewithingroupdiscriminationabilityofthecanceroftheprostateriskassessmentscoreformenwithintermediateriskprostatecancer
AT junghaedo thewithingroupdiscriminationabilityofthecanceroftheprostateriskassessmentscoreformenwithintermediateriskprostatecancer
AT leejooyong thewithingroupdiscriminationabilityofthecanceroftheprostateriskassessmentscoreformenwithintermediateriskprostatecancer
AT kwonjongkyou thewithingroupdiscriminationabilityofthecanceroftheprostateriskassessmentscoreformenwithintermediateriskprostatecancer
AT jehseonguk thewithingroupdiscriminationabilityofthecanceroftheprostateriskassessmentscoreformenwithintermediateriskprostatecancer
AT chokangsu thewithingroupdiscriminationabilityofthecanceroftheprostateriskassessmentscoreformenwithintermediateriskprostatecancer
AT hamwonsik thewithingroupdiscriminationabilityofthecanceroftheprostateriskassessmentscoreformenwithintermediateriskprostatecancer
AT choiyoungdeuk thewithingroupdiscriminationabilityofthecanceroftheprostateriskassessmentscoreformenwithintermediateriskprostatecancer
AT kanghowon withingroupdiscriminationabilityofthecanceroftheprostateriskassessmentscoreformenwithintermediateriskprostatecancer
AT junghaedo withingroupdiscriminationabilityofthecanceroftheprostateriskassessmentscoreformenwithintermediateriskprostatecancer
AT leejooyong withingroupdiscriminationabilityofthecanceroftheprostateriskassessmentscoreformenwithintermediateriskprostatecancer
AT kwonjongkyou withingroupdiscriminationabilityofthecanceroftheprostateriskassessmentscoreformenwithintermediateriskprostatecancer
AT jehseonguk withingroupdiscriminationabilityofthecanceroftheprostateriskassessmentscoreformenwithintermediateriskprostatecancer
AT chokangsu withingroupdiscriminationabilityofthecanceroftheprostateriskassessmentscoreformenwithintermediateriskprostatecancer
AT hamwonsik withingroupdiscriminationabilityofthecanceroftheprostateriskassessmentscoreformenwithintermediateriskprostatecancer
AT choiyoungdeuk withingroupdiscriminationabilityofthecanceroftheprostateriskassessmentscoreformenwithintermediateriskprostatecancer